0001439222-24-000054.txt : 20240305
0001439222-24-000054.hdr.sgml : 20240305
20240305162043
ACCESSION NUMBER: 0001439222-24-000054
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gheuens Sarah
CENTRAL INDEX KEY: 0001881190
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36014
FILM NUMBER: 24720746
MAIL ADDRESS:
STREET 1: C/O AGIOS PHARMACEUTICALS, INC.
STREET 2: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001439222
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-649-8600
MAIL ADDRESS:
STREET 1: 88 SIDNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: AGIOS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20080703
4
1
wk-form4_1709673617.xml
FORM 4
X0508
4
2024-03-01
0
0001439222
AGIOS PHARMACEUTICALS, INC.
AGIO
0001881190
Gheuens Sarah
88 SIDNEY STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
1
Common stock
2024-03-01
4
M
0
3834
0
A
37708
D
Common stock
2024-03-05
4
S
0
1293
32.57
D
36415
D
Common stock
2024-03-01
4
M
0
4000
0
A
40415
D
Common stock
2024-03-05
4
S
0
1349
32.57
D
39066
D
Restricted stock units
2024-03-01
4
A
0
17000
0
A
Common stock
17000
17000
D
Stock options (right to buy)
32.27
2024-03-01
4
A
0
60000
0
A
2034-03-01
Common stock
60000
60000
D
Restricted stock units
2024-03-01
4
M
0
3834
0
D
Common stock
3834
3833
D
Restricted stock units
2024-03-01
4
M
0
4000
0
D
Common stock
4000
8000
D
Includes 2,587 shares purchased through the Company's employee stock purchase plan.
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022.
Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.
The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
/s/ William Cook, as attorney-in-fact for Sarah Gheuens
2024-03-05